IMO 2125

Drug Profile

IMO 2125

Alternative Names: IMO-2125

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Solid tumours
  • Preclinical Colorectal cancer; Lymphoma; Pancreatic cancer
  • Discontinued Hepatitis C

Most Recent Events

  • 01 May 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Monotherapy) in USA (Intratumoural) (NCT03052205)
  • 05 Apr 2017 Pharmacodynamics data from a phase I/II trial Malignant melanoma released by Idera Pharmaceuticals
  • 05 Apr 2017 Pharmacodynamics data from preclinical studies in Pancreatic cancer released by Idera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top